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(57) ABSTRACT 
Techniques for planning the placement of seeds for a brachy-
therapy treatment of diseased tissue include representing a 
placement or non-placement of a seed in each point of a 
predetermined three dimensional grid of potential seed loca-
tions with a binary indicator variable. A tumor and surround-
ing tissue are represented as a predetermined three dimen-
sional tissue grid having a plurality of tissue points. At least 
one of an upper bound and a lower bound for a dose of 
radiation received is associated with each point in the tissue 
grid. An objective value is calculated based on a difference 
at each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the upper 
bound or the lower bound of both. The trial placement of 
seeds is varied and the objective value is again calculated, 
thereby resulting in additional objective values. An optimal 
objective value is selected from the calculated objective 
value and the additional objective values. The planned 
placement of seeds is set based on the trial placement of 
seeds that obtains the optimal objective value. Preferably, 
the tumor and surrounding tissue are represented based on 
biological imaging. A larger upper bound is preferably 
associated with fast-proliferating tumor cells than with 
slowly-proliferating tumor cells. Additionally, the tissue grid 
may represent the tumor and surrounding tissue at a par-
ticular time. In some of these cases, the three dimensional 
grid of potential seed locations at a time of seed insertion is 
mapped to a new grid of potential seed locations at the 
particular time. 
40 Claims, 16 Drawing Sheets 
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BRACHYTHERAPYTREATMENT 
PLANNING METHOD AND APPARATUS 
CLAIM OF PRIORITY 
2 
Manchester Paterson-Parker system, the Quimby system and 
the Paris system. One problem with these known methods is 
that they take a large amount of time (on the order of four 
hours or more) to perform. Thus, treatment strategies 
This application claims priority from Provisional Appli-
cation Serial No. 60/162,236, filed Oct. 29, 1999. This 
application is a Continuation-in-Part of application Ser. No. 
09/375,515, filed Aug. 17, 1999. The entirety of the provi-
sional application and application Ser. No. 09/375,515 are 
incorporated herein by reference. 
5 devised using these methods are typically generated in a 
simulation session several days (or weeks) before placement 
is to be performed. Unfortunately, it is often the case that the 
position of the diseased organ in the operating room differs 
from the position of the organ for which the treatment plan 
BACKGROUND 
10 was intended. In such cases, it may be necessary to change 
the plan in the operating room. What is needed is a method 
and apparatus for quickly (i.e., within minutes) calculating 
a good brachytherapy treatment plan. 
1. Field of the Inventions 
The inventions are related to brachytherapy in general and 15 
are specifically related to the placement and dosage of 
radioactive materials for brachytherapy. 
2. Related Art 
SUMMARY 
Brachytherapy is a type of radiation therapy that involves 
the placement of radioactive sources (referred to herein as 
"seeds") either in tumors (interstitial implants) or near 
tumors (intracavity therapy and/or mold therapy). In this 
treatment approach, radiation from the radioactive sources is 
emitted outward and is limited to short distances. Thus, 
unlike external beam radiotherapy, where radiation must 
traverse normal tissue in order to reach the tumor, brachy-
therapy is much more localized and therefore reduces radia-
tion exposure to normal tissue while allowing a higher 
radiation dose as compared to external beam radiotherapy. 
Brachytherapy has become increasingly popular for the 
treatment of early-stage prostate carcinoma; therefore, the 
present inventions will be discussed with reference to the 
treatment of a prostate tumor. However, those of skill in the 
The aforementioned need is met to a great extent by the 
present invention which provides an integer linear program-
ming model for the placement of seeds and several tech-
niques for finding optimized solutions for seed placement 
20 problems based on the model. The model uses binary 
(referred to herein as "0/1") indicator variables to represent 
the placement or non-placement of seeds in a predetermined 
three-dimensional grid of potential seed locations. In pre-
ferred embodiments, the three dimensional grid of potential 
25 
art will recognize that the present inventions are not limited 
to treatment of prostate tumors and that many other uses of 




In the past, a major limitation to the use of radioactive 
seed implants was the difficulty of accurately placing the 
seeds, which may number from approximately 40-100, in a 
designated geometric pattern. However, with the advent of 
imaging devices such as transrectal ultrasound (TRUS), it 
has become possible to image both the prostate and the 
radioactive seeds. This in turn allows a radiation oncologist 
greater control in the placement of seeds than had been 45 
possible. Seed implantation is commonly performed with a 
template 300 (a plastic slab with a rectangular grid of holes 
in it as shown in FIG. 3), which is attached to a TRUS 
transducer 410 and mounted on a transperineal implantation 
device 400 as shown in FIG. 4. The TRUS transducer 410 50 
transmits images to a dedicated display unit. A series of 
transverse images are taken through the prostate, and the 
TRUS unit displays the template grid superimposed on the 
prostate image. Needles inserted at the appropriate grid 
positions enable seed placement in the target at planned 55 
locations. 
The existence of a suitable procedure for accurately 
placing seeds raises a second issue: determining the optimal 
placement (also referred to as the configuration) of the seeds. 
The placement of seeds should be chosen to satisfy two 60 
criteria: a) the sufficiency of the radioactive dose received by 
the tumor; and b) the minimization of the radioactive dose 
received by surrounding healthy tissue. The large number of 
potential configurations means only a small fraction of 
configurations can be investigated manually. 65 
A number of prior art techniques used to determine seed 
configurations have been used in the past, including the 
locations corresponds to the intersections of the rectangular 
grid of holes of the template discussed above with each of 
a number of parallel "cuts" of the tumor and surrounding 
tissue imaged by an imaging device such as a TRUS or CT 
scanner. The images generated by the imaging device are 
discretized into a number of image points at a granularity 
which may or may not be equal to the granularity of the 
template. The dose delivered to each image point is modeled 
as a linear combination of the indicator variables. A system 
of linear constraints is imposed to attempt to keep the dose 
level at each image point within specified bounds. Branch-
and-bound and genetic algorithms are provided to find 
optimized solutions based on the model. The branch-and-
bound and genetic methods may either maximize the sum of 
rewards associated with achieving the specified bounds or 
minimize the sum of penalties associated with deviating 
from the desired bounds. 
According to one aspect of the invention, techniques for 
planning the placement of seeds for a brachytherapy treat-
ment of diseased tissue includes representing a placement or 
non-placement of a seed in each point of a predetermined 
three dimensional grid of potential seed locations with a 
binary indicator variable. A tumor and surrounding tissue are 
represented as a predetermined three dimensional tissue grid 
having a plurality of tissue points. At least one of an upper 
bound and a lower bound for a dose of radiation received is 
associated with each point in the tissue grid. An objective 
value is calculated based on a difference at each point of the 
tissue grid between an amount of radiation based on a trial 
placement of seeds and the upper bound or the lower bound 
of both. The trial placement of seeds is varied to obtain an 
optimal value for the objective value. A planned placement 
of seeds is set based on the trial placement of seeds that 
obtains the optimal value for the objective value. 
According to one embodiment of this aspect, the tumor 
and surrounding tissue are represented based on biological 
imaging. According to another embodiment, a larger upper 
bound is associated with fast-proliferating tumor cells than 
with slowly-proliferating tumor cells. 
According to another embodiment, the tissue grid repre-
sents the tumor and surrounding tissue at a particular time. 
In some of these embodiments, the three dimensional grid of 
US 6,530,873 Bl 
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potential seed locations at a time of seed insertion is mapped 
to a new grid of potential seed locations at the particular 
time. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The foregoing and other features and advantages of the 
inventions will be more readily understood with reference to 
the following drawings in which: 
FIGS. la and ln illustrate radiation isodose curves (solid 
curves) overlaid on prostate contours (dotted curves) for 
various slices of a patient prostate region for brachytherapy 
treatment plans obtained with branch-and-bound and genetic 
methods according to the present inventions. 
FIGS. 2a-2d are graphs showing the performance of 
various embodiments of brachytherapy treatment planning 
methods according to embodiments of the present inven-
tions. 
FIG. 3 is a front view of a needle template used in 
brachytherapy treatment. 
FIG. 4 is a front view of a transperineal implantation 
device with the template of FIG. 3. 
FIG. SA is a histogram of volume per dose for several 
tissue types using non-conformal seeding treatment on a 
large tumor, according to one embodiment. 
FIG. SB is a histogram of volume per dose for several 
tissue types using conformal seeding treatment (MRS-
guided) on a large tumor, according to another embodiment. 
FIG. SC is a histogram of volume per dose for several 
tissue types using non-conformal seeding treatment on a 
medium tumor, according to one embodiment. 
FIG. SD is a histogram of volume per dose for several 
tissue types using conformal seeding treatment (MRS-
guided) on a medium tumor, according to another embodi-
ment. 
FIG. SE is a histogram of volume per dose for several 
tissue types using non-conformal seeding treatment on a 
small tumor, according to one embodiment. 
FIG. SF is a histogram of volume per dose for several 
tissue types using conformal seeding treatment (MRS-
guided) on a small tumor, according to another embodiment. 
4 
minimal radiation to healthy, normal tissue. The methods 
discussed herein involve mixed integer linear programming 
(MIP) problems. These problems, when solved to proven 
optimality, will produce optimal treatment plans which 
5 satisfy the clinical conditions imposed within the treatment 
planning models. However, since mixed integer program-
ming problems are NP-hard, as of the date of this application 
there exists no known algorithm for solving mixed integer 
programs to proven optimality in "polynomial time." When 
10 
exact algorithms (e.g., branch and bound) are applied to the 
MIP treatment planning models and are allowed to run to 
termination, optimal plans can be obtained. Nevertheless, 
with the present models, these algorithms can produce 
near-optimal plans quickly (within 5-15 minutes). Thus, the 
MIP approach enables clinicians to obtain high-quality treat-
15 ment plans quickly and therefore handle unforseen situations 
arising during seed implantation. Therefore, when the terms 
"optimization" and "optimized" (and variants thereof) are 
used herein, what is being referred to is "near optimum," as 
in a near-optimum treatment plan. 
20 Mixed Integer Programming Formulation Basic Model 
The mixed integer programming model tissue uses 0/1 
variables to record placement or non placement of seeds in 
a predetermined three-dimensional grid of potential loca-
tions. The locations correspond to the intersections of the 
25 needles in the template used to place the seeds with each of 
a number of parallel cuts (imaged by an imaging device such 
as a TRUS or CT scan device) of the tumor site and 
neighboring healthy organs. If a seed is placed in a specific 
location, then it contributes a certain amount of radiation 
30 
dosage to each point in the images. The images themselves 
are discretized at a granularity that is conducive both to 
modeling the problem accurately and to enabling computa-
tional approaches to be effective in obtaining solutions in a 
timely manner. In an application of the method to treat 
35 
prostate carcinoma, points on the image 2.5 mm apart were 
selected, resulting in approximately 800-1600 points within 
the images themselves, plus an additional 300--600 points 
representing the contours of the images. 
The dose contribution of a seed to a point is calculated by 
40 
assuming each seed is well approximated by a point source. 
In particular, at a distance r from a seed the dose contribution 
is given by: 
FIG. 6Ais a graph showing coverage ( <1) and conformity 
(>1) ratios for an effective planning volume based on a 
45 
single period according to one embodiment. 
D(r) = ATF(r) 
,2 
(1) 
FIG. 6B is a graph showing coverage ( <1) and conformity 
(>1) ratios for an effective planning volume based on two 
periods according to another embodiment. 
where A is the initial activity of the seed, T is the mean life 
of the radioisotope, and F(r) is the radial dose factor. In 
preferred embodiments, an appropriate table of dose factors 
DETAILED DESCRIPTION 50 associated with a discrete set of distances is selected (e.g., 
see Mohan and Anderson 1982 Memorial dose distribution 
The present inventions will be discussed with reference to 
preferred embodiments of methods for planning brachy-
therapy treatments. Specific details, such as the use of a 
prostate tumor to illustrate the methods, type of imaging 55 
device, specific dimensions, numbers of seeds, etc., are set 
forth in order to provide a thorough understanding of the 
present inventions. The preferred embodiments discussed 
herein should not be understood to limit the inventions. 
computation service---Brachy II interstitial and intracavi-
tary dose computation program user's guide Memorial 
Hospital, Appendix I; Anderson et al. 1981, Clinical dosim-
etry with I-125, Modern Interstitial and Intracavitary 
Radiation Cancer Management George F W (Ed) Masson 
Publishing USA Inc. 9-15; 1993, A nomograph for perma-
nent implants of Palladium-103 seeds Int. J. Radiat. One. 
Biol. Phys. 27 129-135, the contents of which are incorpo-
In an ideal situation, it is desirable to develop a treatment 
plan that provides a sufficient radiation dose (as prescribed 
60 rated by reference herein), and linear interpolation is used to 
estimate dose factors for distances not in the table. The 
by the clinician) to the tumor region while sparing the 
neighboring healthy tissue from any radiation exposure. 
However, due to the close proximity of tumor regions and 
healthy tissue, such a treatment plan does not exist with 65 
today's technology. Clinically, in designing treatment plans, 
one strives to satisfy the prescription dose while providing 
source emission is actually anisotropic. However, because 
the source orientation in the patient cannot be controlled, it 
is assumed that seeds are randomly oriented. 
Given the grid of potential seed locations, the total dose 
level TD at each point P (in Euclidean coordinates) is given 
by: 
US 6,530,873 Bl 
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some (possibly all) of the decision variables are restricted 
to be integer valued, 
the decision variables are constrained by a system of 
linear equations and/or inequalities, and 
the objective function to be maximized or minimized is 
expressed as a linear function of the decision variables. where xj is a 0/1 indicator variable for recording placement 
or non placement of a seed in grid position j, Xj is a vector 
corresponding to the coordinates of grid point j, n is the 
number of grid points (potential seed locations), and 11·11 
denotes the Euclidean norm. 
Associated with each point P are target lower and upper 
bounds, Lp and Up, on the total radiation dose delivered to 
point P. These bounds are commonly expressed as multiples 
In order to formulate the basic model outlined above in 
the mixed integer programming framework, additional vari-
ables are introduced to capture the objective goals. For 
10 objective (a), one needs to capture when a point satisfies the 
various bound conditions. Thus, the 0/1 variables v p, w P and 
Zp are introduced with the following interpretations: 
of a desired prescription dose to the diseased organ, where 
all points in the same anatomical structure are assigned 15 
identical bounds. 
Within this framework, the problem of finding a suitable 
configuration of seeds is interpreted as that of finding a 
solution to the following system of linear inequalities: 
n 
~ D(llP- X1ll)x1 <: Lp 
j=l 
n 
~ D(llP- X1ll)x1:;; Up, 
j=l 
(3) 
where each of the variables xj is restricted to take on either 
20 
25 
0 or 1. Unfortunately, it is not possible to satisfy all such 
inequalities simultaneously as discussed above. Indeed, due 30 
to the inverse square factor (see equation (1) above), the 
dose level contribution of a seed to a point less than 0.3 units 
away, for example, is typically larger than the target upper 
bound for the point. 
The goal is to devise methods for assigning 0/1 values to 35 
the x/s so that the system is satisfied "to the greatest extent 
possible" as discussed above. It is natural to consider 
optimization techniques to achieve this goal. It is necessary 
to select some metric for gauging "goodness" of solutions 
before appropriate optimization techniques can be 40 
employed. Two general classes of objectives may be used: 
(a) maximize the sum of rewards associated with achiev-
ing the desired bounds; 
{l, if TD(P) <:Lp 
Up= 
{O, otherwise 
{l, if TD(P):;; Up 
Wp = 
{O, otherwise 
{l, if Lp:;; TD(P):;; Up 
Zp = {O, otherwise 
Then the MIP (mixed integer program) for objective (a) 
(referred to herein as MIP A) can be stated as: 
maximize 
. ~ (a:pVp + f3pwp + YPZP) 
subiect to P 
n 
~ D(llP- X1llJx1 +Np(! - vp) <: Lp 
j=l 
n 




Vp, Wp, Zp, Xj E {0, 1} 
(MIP A) 
where Mp and NP are suitably chosen positive constants 
(discussed further below). If a solution is found such that 
Vp=l, then the term Np(l-vp) in the first inequality in (MIP 
A) is zero; and hence, the target lower bound for the dose 
level at point P is satisfied. Similarly, if w p=l, the term 
Mp(l-wp) in the second inequality in (MIP A) is zero; and 
hence, the target upper bound for the dose level at point P is 
satisfied. Finally, if Zp=l, then both Vp=l and Wp=l, and (b) minimize the sum of penalties associated with devi-
ating from the desired bounds. 
In preferred embodiments, objective (a) is implemented 
by introducing three nonnegative weights (rewards) for each 
point. If the dose delivered to point Pis greater than or equal 
45 consequently, the dose level delivered to point P satisfies 
both bounds. The objective, maximize ~p(apvp+~pwp+ 
ypzp), is what drives the optimization engine to assign a 
value of 1 to the variables v p, w P and Zp. In particular, at 
to the target lower bound, Lp, the objective value is incre-
mented by ap~O; if the dose delivered is less than or equal 50 
to the target upper bound, Up, the objective value is incre-
mented by ~P~O; and finally, if the dose delivered satisfies 
both bounds, the objective value is incremented by YP~O. 
To implement objective (b), two nonnegative weights per 
point are used in preferred embodiments. If the dose deliv- 55 
ered to a point does not satisfy one of the target bounds, a 
penalty, equal to the deviation from the target bound scaled 
by the appropriate weight, is added to the objective value. 
That is, if TD(P)<Lp, the objective value is incremented by 
ap[Lp-TD(P)], where ap~O. Similarly, if TD(P)>Up, the 60 
objective value is incremented by ~p(TD(P)-Up], where 
~P~O. The bounds and weights used in a specific prostate 
cancer implementation are specified below in Tables 1 and 
optimality, the converse of each of the above conditional 
statements is true, provided the associated objective coeffi-
cient is strictly positive. Formally, 
if ap>O, then at optimality, Vp=l if and only if the target 
lower bound at point P is satisfied; 
if ~p>O, then at optimality, Wp=l if and only if the target 
upper bound at point P is satisfied; and 
if yp>O, then at optimality, Zp=l if and only if the dose 
delivered to point P satisfies both bounds. 
The argument to establish the "if" direction in each of the 
above statements is elementary. For example, consider the 
first statement. If the target lower bound at point P is 
satisfied, but v p=O, then the current solution is not optimal 
since a better solution can be found by modifying the current 
solution. The modified solution is selected identical to the 
2. 
Incorporating the Objectives 
A mixed integer linear program (MIP) is an optimization 
problem where: 
current solution except the variable v P is assigned the value 
65 1 instead of 0. Thus, the modified solution has an objective 
value that exceeds the current (supposedly optimal) solution 
by ap. 
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The role of the constants Np and Mp in (MIP A) is to 
ensure that there will be feasible solutions to the mathemati-
8 
points representing the contours of the structure, while other 
points within the diseased structure could be restricted by a 
much wider range of bounds (e.g., 100% and 160% of the 
prescription dose). In this way, the dose to tissue outside of 
cal model. In theory, these constants should be chosen large 
enough so that if v P or w P is zero, the associated constraint 
in (MIP A) will be satisfied regardless of how the 0/1 
variables xj are assigned. In practice, the choice is driven by 
computational considerations of the optimization algorithm 
being used and/or by decisions by the radiation oncologist. 
For the genetic algorithm described below, these constants 
are irrelevant since the algorithm does not depend on the 
constraints at all. For the branch-and-bound algorithm 
described below, the constants are needed, and it is advan-
tageous computationally to assign values that are as small as 
possible. The radiation oncologist can guide the selection of 
the constants by either declaring absolute extremes on 
acceptable radiation dose levels delivered to each point (note 
that U p+Mp is the absolute maximum dose level that will be 
delivered to point P under the constraints of (MIP A), and 
Lp-Np is the absolute minimum), or by estimating the 
number of seeds needed for a given plan. In the latter case, 
if the number of seeds needed is estimated to be between 80 
and 120, for example, then the constant Np can be taken to 
5 the diseased structure is effectively controlled. The selection 
of a set of weights and bounds may be guided by analysis of 
solutions via other criteria, such as isodose curves and 
dose-volume histograms. Such criteria helped to influence 
the choice of weights and bounds for application of the 
10 
models to the prostate cancer cases discussed herein. 
Model Variations 
Various simplifications to (MIP A) are possible depending 
on how the objective coefficients and bounds are selected. 
For example, if it is desired to add a reward only if both 
target bounds at point P are satisfied, then one would select 
15 up=O, ~p=O and yp>O. In this case, the variables up and Wp 
can be replaced with Zp and the constraints Zp~Vp and 
Zp~Wp can be eliminated. Another opportunity for simpli-
fication may arise if P represents a point in healthy tissue. In 
this case it may be reasonable to assign Lp=O; then the 
20 variable .. pand the constraints involving up can be elimi-
nated. 
be LP minus the sum of the smallest 80 of the values 
D(llP-X)I), and the constant Mp can be taken to be the sum 
of the largest 120 such values minus Up· Selection in this 25 
fashion will ensure that no plan having between 80 and 120 
seeds will be eliminated from consideration. 
For objective (b), nonnegative continuous variables YP 
and Zp are introduced to capture the deviations of the dose 
level at a given point from its target lower and upper bounds, 30 
respectively. The MIP for objective (b) (MIP B) can be 
stated as: 
When the target bounds LP and UP are expressed as 
multiples of a target prescription dose, T p, another natural 
approach is to capture the deviations from T P directly. In our 




where YP is a continuous variable, unrestricted in sign. In the 
objective, one can then minimize the q norm of the vector y 
of all deviations; i.e., minimize llYllq=(~PIYPl'l)I/q. 
35 Another enhancement that could be incorporated into any 
n 




of the above models is the allowance of alternative seed 
types, or possibly same seed types but having different 
source activities. There are a variety of radioactive sources 
that are used for brachytherapy, including cesium-137, 
~ D(llP- X1llJx1 -Zp:;; Lp 
j=l 
YP <: 0, Zp <: 0, Xj E {0, 1). 
40 iridium-192, palladium-103, iodine-125, and gold-198, each 
of which has its own set of exposure rate constants. 
Typically, however, a single seed type is used in a given 
treatment plan. This fact is, in part, due to the difficulty of 
designing treatment plans with multiple seed types. The 
When applied to (MIP B), an optimization engine will 
attempt to assign values to the 0/1 variables (i.e., select seed 
positions from the set of potential seed positions) so that the 
weighted sum of deviations from the target bounds, 
~p(upyp+~pwp), is minimized. Note that it is the objective 
that drives the optimization engine to select Ep and Zp to 50 
represent the deviations. Indeed, at optimality, any con-
straint for which yp(zp) is non zero will be satisfied at 
equality, provided that up(~p) is strictly positive. 
45 allowance of multiple seed types can easily be incorporated 
into the MIP model-{)ne need only modify the total dose 
level expression (2) as: 
In both models, the objective function weights (up, ~p, 
yp) should be selected according to the relative importance 55 
of satisfying the associated bounds. For example, weights 
associated with an upper bound on the radiation dose for 
points in a neighboring healthy organ may be given a 
relatively larger magnitude than weights associated with an 
upper bound on the dose level for points in the diseased 60 
organ. In a similar spirit, the lower and upper bounds, Lp and 
UP, can be selected to guide the optimization engine to select 
solutions with desired characteristics. Given a target pre-
scription dose for the diseased structure, the dose delivered 
to points on the boundary of the structure could be tightly 65 
controlled by appropriately selecting lower and upper 
bounds (e.g., 100% and 115% of the prescription dose) for 
(5) 
Here, xij is the indicator variable for placement or non 
placement of a seed of type i in grid location j, and D;(r) 
denotes the dose level contribution of a seed of type i to a 
point r units away. In this case, a constraint restricting the 
number of seeds implanted at grid point j is also needed: 
~ixij~ 1. It remains to be tested whether the added flexibility 
of allowing multiple seed types will have a substantial 
impact on the number of points at which the target dose 
levels can be satisfied. Computationally, the optimization 
problem may prove to be more difficult due to the increased 
number of 0/1 variables. 
Finally, the basic model also allows the incorporation of 
additional physical constraints. For example, one could 
incorporate constraints to control the percentage of each 
tissue structure satisfying the specified bounds. 
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Alternatively, one could, if desired, constrain the total num-
ber of seeds and/or needles used. 
Computational Techniques 
Two computational methods have been applied to 
instances of the models presented in the previous section to 
find an optimized solution. The first method, known as 
branch-and-bound, is an exact method commonly employed 
in solving integer programming problems. A branch-and-
bound algorithm will, if allowed to run to completion, 
terminate with an optimal solution. Moreover, the "intelli-
gent" search mechanism of the branch-and-bound method 
enables large sections of the solution space to be eliminated 
from consideration (knowing that no solution within can be 
optimal) without actually examining each solution within-
thereby conserving computing time. 
The second approach is a genetic algorithm. A genetic 
algorithm is a heuristic procedure, and is applied in this case 
without taking into account any constraints in the model. It 
10 
the original MIP with a greater objective value than the one 
already obtained. Hence, no further exploration of this other 
node is needed, and the node is said to be fathomed. 
Two other criteria for fathoming a node are obvious: if the 
5 associated LP is infeasible, or if the optimal solution of the 
LP has integral values for all relaxed binary variables, then 
no further exploration of the node is required. In the latter 
case, the optimal objective value of the LP will be compared 
with the current lower bound, and the lower bound will be 
10 updated if needed. The tree search ends when all nodes are 
fathomed. 
A variety of strategies have been proposed for intelli-
gently selecting branching variables and nodes to process. 
However, no strategy stands out as being best in all cases. 
15 What has become clear from recent research in computa-
tional MIP, is that branch-and-bound is most effective when 
coupled with other computational devices, such as problem 
preprocessing, primal heuristics, global and local reduced-
is based on the idea of randomized enumeration, where the 
randomization is guided by operations designed to mimic 20 
the phenomena of crossover and mutation that naturally 
occur in the reproduction of species. The notion that only the 
best fit individuals survive to pass on their genetic material 
cost fixing, and cutting planes. The reader can refer to the 
article by Lee and Mitchell (1999, Branch-and-bound meth-
ods for integer programming Encyclopedia of Optimization 
Floudas C A and Pardalos P M (Eds.) (The Netherlands: 
Kluwer Academic Publishers), the contents of which are 
incorporated by reference herein), for a concise description 
of branch-and-bound methods for integer programming. The 
books by Schrijver (1986, Linear and Integer Programming 
is mimicked by biasing the selection of parents by using a 
"fitness" function based on the objective function that is to 25 
be optimized. Although genetic algorithms have been 
applied with some success to combinatorial optimization 
problems, they are only heuristic search strategies. No test 
for optimality is embedded into a genetic algorithm. The 
user of the algorithm dictates that the algorithm should 30 
terminate either after a specified number of generations, or 
after the observed change in fitness scores between consecu-
tive generations remains sufficiently small. 
(New York: Wiley)), Nemhauser and Wolsey (1988, Integer 
and Combinatorial Optimization (New York: Wiley)) and 
Parker and Rardin (1988, Discrete Optimization (New York: 
Academic Press), the contents of which are incorporated by 
reference herein), contain detailed expositions on integer 
programming and related computational issues. 
The numerical work of the preferred embodiments dis-
cussed herein is based on a branch-and-bound MIP solver Branch-and-Bound Method 
The classical approach to solving linear 0/1 mixed integer 
programs is branch-and-bound. This is a tree search 
approach where, at each node of the tree, certain binary 
variables are fixed to zero or one, and the remaining binary 
variables are relaxed (i.e., allowed to assume any value 
between zero and one). This results in a linear program (LP) 
being associated with each node of the tree. The LP at the 
root node is simply the original 0/1 MIP instance with all of 
the binary variables relaxed. The tree is constructed such 
that the binary is variables fixed in a parent node will be 
fixed identically in any of its children, and each child will 
have an additional binary variable fixed to zero or one. 
Typically, children are formed in pairs as follows. Assume 
that the LP at a given node is solved, and one or more of the 
relaxed binary variables is fractional in the optimal solution. 
One selects such a fractional binary variable and branches 
on it. That is, two child nodes are formed; one with the 
selected binary variable fixed to zero, and the other with the 
selected binary variable fixed to one. Of course, each child 
also inherits all of the fixed binary variables of its parent. 
Note that the objective value of a child node can be no 
greater (in the case of maximization) than the objective 
value of its parent. 
35 that is built on top of a general-purpose mixed integer 
research code (MIPSOL) (Lee 1997, Computational expe-
rience of a general purpose mixed 0/1 integer programming 
solver, Technical Report School of Industrial and Systems 
Engineering Georgia Institute of Technology, the contents of 
40 which are incorporated by reference herein). The general-
purpose code, which incorporates all of the above mentioned 
computational devices, has been shown to be effective in 
solving a wide variety of large-scale real-world MIP 
instances. A complete description of the solver and com-
45 parisons between numerical strategies are described in Lee 
et al. (1998a, Computational issues for a mixed integer 
programming approach to treatment plan optimization for 
radiation therapy, Technical Report School of Industrial and 
Systems Engineering Georgia Institute of Technology; 
50 1998b, Mixed integer programming approaches to treatment 
planning for brachytherapy-application to permanent pros-
tate implants, Technical Report School of Industrial and 
Systems Engineering Georgia Institute of Technology, the 
contents of which are incorporated by reference herein). 
55 Genetic Method 
If the linear program at a given node is solved and the 
optimal solution happens to have integral values for all the 
relaxed binary variables, then this solution is feasible for the 60 
original 0/1 mixed integer program. Once a feasible solution 
for the original problem is found, the associated objective 
value can be used as a lower bound (in the case of 
maximization) for the objective values of LP's at other 
nodes. In particular, if an LP at another node is solved, and 65 
its objective value is less than or equal to the lower bound, 
then none of its children could yield a feasible solution for 
A genetic algorithm is a heuristic optimization method 
modeled on the biological mechanisms of evolution and 
natural selection (e.g., see Buckles 1992, Genetic Algo-
rithms (Los Alamitos, Calif.: IEEE Computer Society 
Press); Wasserman 1993, Advanced Methods in Neural 
Computing (New York: Van Nostrand Reinhold, the contents 
of which are all incorporated by reference herein). In nature, 
the characteristics of an organism are encoded in streams of 
DNA known as chromosomes. Likewise, in a genetic 
algorithm, a potential solution to a problem is encoded as a 
stream of symbols over a given alphabet. Given an initial 
population of individuals (i.e., potential solutions encoded 
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as symbol streams), a subset of the population is selected to 
parent offspring for the next generation. The parent selection 
process is stochastic, but biased towards selecting those 
individuals that are most fit, as measured by a pre-selected 
fitness function (e.g., the objective function that one is trying 5 
to optimize). 
After the parents are selected, they are paired off and 
mated. That is, subsections of two parent symbol streams are 
interchanged, forming two new members for the next gen-
eration. This is analogous to cross-over in biological 10 
reproduction, where a child's genetic composition is a 
combination of its parents. Mutations are also possible. This 
is typically implemented by randomly selecting a child 
symbol stream and randomly altering one of its symbols. 
The algorithm can be terminated after a specified number 15 
of generations have been created (usually several hundred), 
or by examining when the difference between the maximum 
and minimum fitness values between consecutive genera-
tions remains less than a specified threshold for a number of 
generations. Upon termination, the individual in the final 20 
generation with the largest fitness value is selected as the 
operative solution to the problem at hand. 
Obviously, many variations on implementation specifics 
for a genetic algorithm are possible. For the case at hand, a 
given seed configuration can be viewed as a stream of O's 25 
and l's. In terms of the notation in the previous section, such 
a stream is analogous to an instantiation of the binary 
variables xF 
The genetic algorithm described herein begins by ran-
domly generating 600 binary data streams of length n, all 30 
having the same number of l's (an initial estimate of the 
number of seeds required). From this set of 600, the top 
scoring 15, excluding duplicates, are selected for the first 
generation. Subsequent generations all have 15 members as 
well. To create the next generation from the current 35 
generation, 14 of the 15 data streams are selected to be 
involved in a crossover and paired up. For the crossover 
operation, non-contiguous randomly selected bits are inter-
changed. A uniformly distributed random number between 0 
and n/2 is used to determine the number of bits to be 40 
interchanged between parent pairs. 
After cross-over occurs, the mutation operation is per-
formed five times. Each operation involves randomly select-
ing one of the 15 data streams (14 newly created data 
streams resulting from crossover, plus the one data stream 45 
that was not selected to be a parent) and randomly selecting 
a bit to be inverted. Note that the same data stream could be 
selected two or more times for mutation, and, though 
unlikely, one mutation could cancel the effect of a previous 
12 
represent the prostate. Contour points specified the boundary 
of the prostate in each of the images; and the regions 
determined by each boundary were populated with uni-
formly spaced points, referred to herein as uniformity points. 
Within each image, both the contour points and the unifor-
mity points were spaced 2.5 mm apart in each dimension. 
The images themselves were spaced 5 mm apart. In addition 
to the discretization data, isotope source activities and radial 
dose factors, and coordinates of potential seed locations 
were also specified. 
The results described herein facilitate two objectives: (1) 
to assess the effects of using the different models and model 
parameters, and (2) to compare plans obtained by the 
branch-and-bound optimization approach to those obtained 
by the genetic algorithm approach. To facilitate objective 
(1), a single optimization algorithm (the branch-and-bound 
algorithm) was applied to each model and the objective 
weights were varied in an identical manner across models. 
Comparison between treatment plans was based on quanti-
tive measures of the percentage of points in each anatomical 
structure achieving specified target dose bounds, as well as 
by visual inspection of dose-volume histograms and isodose 
curves. To facilitate objective (2), a single model and 
objective weight combination was selected for each method, 
and each method was applied to all 20 patient cases. 
Comparison between treatment plans obtained with the two 
methods was performed using the same criteria as in goal 
(1). 
Choice of Model Parameters 
The models described above offer many degrees of free-
dom for assigning target bounds and objective function 
weights. For example, each point in the discretization can be 
assigned its own unique set of bounds and weights. In 
preferred embodiments, however, it is reasonable to stratify 
the assignment of bounds and weights by point type. Thus, 
for each point type (i.e., contour, uniformity, rectum, and 
urethra), a target lower bound, a target upper bound, and 
three objective function weights were assigned. 
The target bounds used are shown in Table 1. They are 
















target prescription dose to the prostate, which was patient 
dependent. Note that the lower bound for rectum points was 
mutation. 
In order to ensure that the current best solution is not lost, 
the strategy of elitism is employed. That is, the data stream 
with the highest fitness value is passed on unchanged to the 
next generation. This is implemented by simply overwriting 
one of the newly created children. More details on the 
implementation of the genetic algorithm can be found in 
Silvern (1998, Automated OR prostate brachytherapy treat-
ment planning using genetic optimization, Ph.D. Thesis, 
Department of Applied Physics, Columbia University, New 
York, the contents of which are incorporated by reference 
herein). 
50 set to zero, since there is no therapeutic reason to deliver any 
radiation to the rectum. In contrast, since the urethra is 
surrounded by the prostate, too little dosage to the urethra 
may be indicative that diseased tissue proximal to the 
urethra is not receiving adequate dosage. Hence, a positive-
Numerical Experiments 
Data from 20 prostate cancer patients were used to test the 
models and algorithmic approaches discussed above. The 
data included points representing the discretization of three 
anatomical structures-the prostate, the rectum, and the 
urethra. Two distinct categories of points were used to 
55 valued lower bound for urethra points was specified. One 
may argue that there is no therapeutic reason to place upper 
bounds on the dose delivered to points representing the 
prostate. However, from the optimization standpoint, there is 
an important reason. If no upper bounds are specified, the 
60 optimization engine will be guided by an objective that 
emphasizes the satisfaction of lower bounds, and thus will 
steer towards solutions that have an over abundance of 
seeds. The upper bounds on uniformity and contour points 
effectively help to limit the number of seeds selected, and 
65 thereby confine the prescription dose to the diseased tissue. 
Extensive computational experiments were performed to 
study the effects of using different objective function 
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weights for the various point types. Initial observations 
revealed that it was advantageous to assign weights based, 
at least in part, on the number of points in the discretization 
of each "structure." Here, we summarize results for the 
weight combinations given in Table 2. The symbols n" nu" 
nun' and nc: denote, respectively, the 
TABLE 2 
Combination Parameter Rectum Urethra Uniform Contour 
a 0 nun/nm nlll/nc 
13 nrm/n, nun/nm nun/Ile 
0 0 0 0 
2 a 0 nrm 
13 nrm nrm 
0 0 0 0 
3 a 0 0 0 0 
13 0 0 0 0 
nrm/n, nun/nm nun/Ile 
4 a 0 0 0 0 
13 0 0 0 0 
nrm nrm 
number of rectal points, the number of urethra points, the 
number of uniformity points, and the number of contour 
points. For the 20 cases considered, nun ranged between 568 
and 2206, nc between 261 and 692, and nr and nur between 
6 and 10. (In each image, the positions of the rectum and 
urethra were each represented by a single point.) 
Combinations 1 and 3 correspond to giving equal weight 
to each structure by taking into account how many points 
represent each structure. The uniformity points are the most 
numerous, so each uniformity point is weighted by 1, and 
each non uniformity point is weighted by the number of 
uniformity points divided by the number of points repre-
senting the associated structure. In combinations 2 and 4, 
each point representing the prostate is weighted by 1, and the 
rectum and urethra points are weighted by the number of 
uniformity points. The use of the large weights on rectum 
and urethra points in Combinations 2 and 4 greatly increases 
the likelihood that the optimization engine will select a 
solution for which the dose delivered to these points will be 
within the target bounds. 
Including both combinations 1 and 2 (and similarly, 3 and 
4) the numerical tests provided a way of gauging the 
sensitivity of treatment plans obtained to relatively small 
changes in contour point priority. The motivation for weight-
ing contour points higher is to drive the optimization engine 
to select a solution in which the target prescription dose 
conforms well to the prostate, thereby reducing excessive 
exposure to nearby healthy tissue. In the 20 cases 






rithm were those associated with the first feasible solutions 
found (i.e., integer-valued, but not necessarily optimal), and 
were obtained within 300 CPU seconds. For the genetic 
algorithm, typically 1000 generations were used for gener-
ating a treatment plan, requiring approximately 900 CPU 
seconds. 
For the evaluation of treatment plans, a much finer grid (1 
mm spacing in each dimension) of uniformity points was 
used. This not only helped to obtain a more complete 
representation of dose delivered to the prostate, it also 
helped to eliminate the bias of testing a plan with the same 
data used to generate it. Plans were also evaluated using a 
smaller upper bound on the contour points than used in the 
models themselves. Visual inspection of isodose curves and 
dose-volume histograms showed that plans for which a 
significant number of contour points were within 115% of 
the prescription dose conformed quite well to the prostate 
volume. Hence, although the models upon which the plans 
were generated used an upper bound of 1.6 times the 
prescription dose, a factor of 1.15 was used in the evaluation 
phase. 
In both (MIP A) and (MIP B), the initial plans obtained 
using weight combination 2 satisfied more bound conditions 
for urethra and rectum points than those obtained using 
25 weight combination 1. In (MIP A2) (i.e., (MIP A) with 
weight combination 2) 100% of the urethra and rectum 
points satisfied both bounds in 17 cases, while in the 
remaining 3 cases, approximately 80% of the points satisfied 
both bounds. In contrast, for (MIP Al) only 8 cases achieved 
30 100% satisfaction of both bounds. In the remaining 12 cases, 
the percentage of points satisfying the upper bound ranged 
from 50-100%, and the percentage of urethra points satis-
fying the lower bound ranged from 80-100%. (Again, rectal 
points automatically satisfy their specified lower bound of 
35 zero.) For (MIP B2), in all 20 cases, all urethra points 
satisfied the lower bound and over 85% of rectum and 
urethra points satisfied the upper bound. For (MIP Bl), in 19 
cases, all urethra points satisfied the lower bound, and in all 
20 cases, between 40-85% of urethra and rectum points 
40 satisfied the upper bound. There are two factors contributing 
to the observed results. First, and likely more important, the 
urethra and rectum points are weighted significantly heavier 
in combination 2 than in combination 1. Second, the contour 
points are weighted somewhat less in combination 2 than in 
45 combination 1. Thus, for (MIP A2) and (MIP B2) the 
optimization engine will tend to select solutions in which the 
urethra and rectum points satisfy their bounds, and at the 
same time give relatively less emphasis (compared with 
(MIP Al) and (MIP Bl)) to contour point bounds. 
By the same token, one would expect more contour points 
to satisfy the measured bounds when using weight combi-
nation 1 than when using weight combination 2. We 
observed this to a small degree for (MIP A), but since the 
ratios nun/nc were typically 3 or less, there was not a great 
so the shift in priority is relatively small. Finally, the relative 50 
importance of allocating rewards (penalties) for satisfying 
(violating) bounds separately versus satisfying both bounds 
simultaneously can be analyzed by comparing results of 
using weight combinations 1 and 3, as well as weight 
combinations 2 and 4. 55 difference. Among the 20 cases, for (MIP Al) on average 
31 % of contour points satisfied both bounds, 53% satisfied 
the upper bound, and 79% satisfied the lower bound. The 
corresponding percentages for (MIP A2) were 28%, 51 %, 
and 77%. In 16 cases, there were at least as many contour 
Note that all four weight combinations are directly appli-
cable to (MIP A), whereas only combinations 1 and 2 are 
directly applicable to (MIP B). However, combinations 3 
and 4 could be applied to a modified form of (MIP B) 
involving additional constraints and variables. Also note that 
since the lower bound for rectal points is set to zero (see 
Table 1), these points always achieve the lower bound; and 
consequently, there is no need to allocate a positive reward 
to the a parameter for the rectum in combinations 1 and 2. 
Numerical Results 
All treatment plans discussed herein were generated on 
166 Mhz machines. Plans from the branch-and-bound alga-
60 points satisfying both bounds for (MIP Al) as there were for 
(MIP A2). The increase in the percentage of points satisfying 
both bounds ranged from 0% (5 cases) to 12%. In the four 
remaining cases, there were modestly more contour points 
(less than 2%) satisfying both bounds in (MIP A2) than in 
65 (MIP Al). In 14 cases, the percentage of contour points with 
dose level less than the upper bound was higher (by 
0%-13%) in (MIP Al) than in (MIP A2), while in 6 cases it 
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was lower (by 0%-4%). Perhaps more significant, the per-
centage of contour points at a dose level greater than 250% 
of the prescription dose was lower (by 0.3%-2.5%) in every 
patient case in (MIP Al) compared to (MIP A2). These 
results provide evidence to support the hypothesis that (MIP 5 
A) allows fairly fine-grain control of dose to contour points 
via incremental changes in weights associated with satisfy-
ing contour point bounds. 
The results regarding contour points for (MIP B) under 
weight combinations 1 and 2 were mixed. In particular, 10 
weight combination 1 did not, in general, lead to the 
satisfaction of more bound conditions on contour points than 
did weight combination 2. This, together with the discussion 
in the previous paragraph, suggests that results of small 
weight adjustments to (MIP B) are less predictable than 15 
those to (MIP A). 
The primary issue for uniformity points concerns the 
satisfaction of the lower bound so as to ensure the prostate 
receives a full tumoricidal dose. For all models and weight 
combinations, on average 96%-97% of uniformity points 20 
achieved a dose level greater than or equal to the prescrip-
tion dose. Of particular interest, however, is that there was 
one patient case (Patient 17) in which all models scored well 
below average (83%-87%). This anomaly occurred for the 
genetic algorithm as well as the branch-and-bound algorithm 25 
(see Table 3. and FIG. 2). Visual inspection of the contours 
for this case showed that they tapered off unusually sharply 
at both ends. The fact that all models and weight combina-
tions returned similar results for this case suggests that this 
distinguishing physical feature of the prostate makes it 30 
significantly more difficult to find a plan with "desired" 
characteristics. 
When the branch-and-bound algorithm was applied to 
(MIP A) using weight combinations 3 and 4, among the 20 
Branch-and-Bound 
16 
patient cases, on average only 50% of the uniformity points 
satisfied the lower bounds, and less than 10% of the contour 
points were within both bounds (approximately 8% satisfied 
the lower bound, while over 90% satisfied the upper bound). 
These results suggest that initial solutions obtained from the 
branch-and-bound algorithm for these latter weight combi-
nations yield plans that are inferior to those obtained via 
weight combinations 1 and 2. Overall, for the 20 cases 
considered, the best treatment plans generated from the 
branch-and-bound algorithm resulted from its application to 
(MIP Al). 
In contrast, empirical tests using the genetic algorithm 
showed that, among the weight combinations used to test it, 
it yielded the best plans when applied to (MIP A) and a 
variant of weight combination 3 in which the y parameters 
were set to 35, 40, 1, and 3 for the rectum, urethra, 
uniformity, and contour points, respectively (Silvern 1998, 
Automated OR prostate brachytherapy treatment planning 
using genetic optimization, Ph.D. Thesis, Department of 
Applied Physics, Columbia University, New York). Table 3 
shows a comparison of plans from the branch-and-bound 
algorithm applied to (MIP Al) and the genetic algorithm 
applied to (MIP A) using the above weights. Patient cases 
are categorized according to the prescription dose. The 
source activity of seeds used is specified in the column 
labeled Activity. For each algorithm, the first three 
columns-labeled~ 100%, ~ 115%, ~ 250%-correspond 
to the percentage of contour points satisfying at least 100%, 
at most 115%, and above 250% of the prescription dose, 
respectively. Next, the column ~100% indicates the per-
centage of uniformity points satisfying at least 100% of the 
prescription dose. Finally, No. Seeds denotes the number of 
seeds used in the generated plans. 
TABLE 3 
Genetic Algorithm 
Contour Uniformity Contour Uniformity 
Activity Percent of Points Achieving Percent of Points Achieving 
Pat. (mCi) "';100% ~115% ~250% "';100% No. Seeds "';100% ~115% ~250% "';100% No. Seeds 
100 Gy 
0.592 77.5 50.8 2.02 97.3 40 76.5 54.4 3.70 96.1 40 
2 0.450 85.2 60.8 0.96 99.4 51 94.8 41.3 3.85 99.6 54 
3 0.334 73.2 50.9 3.26 94.5 51 71.6 57.6 3.26 93.2 50 
4 0.400 87.3 55.0 2.16 98.5 42 83.2 46.7 6.47 97.5 42 
5 0.590 80.5 52.8 1.08 98.5 50 84.8 46.1 2.48 97.1 51 
0.450 86.4 48.3 2.69 98.6 64 87.5 43.6 7.47 98.7 62 
7 0.400 90.1 43.5 4.80 97.0 39 84.8 43.9 7.58 96.1 38 
8 0.450 80.0 55.2 1.85 98.3 44 93.0 37.6 4.85 99.4 46 
9 0.500 90.0 43.4 2.22 98.8 32 90.8 39.7 6.39 98.0 32 
120 Gy 
10 0.468 81.3 42.6 1.15 93.9 28 72.8 59.0 4.60 92.7 28 
160 Gy 
11 0.520 75.5 58.0 0.87 96.4 85 72.4 52.9 3.47 94.2 82 
12 0.544 75.6 48.8 2.85 95.1 58 73.9 48.7 5.69 93.0 56 
13 0.450 81.1 59.5 0.47 98.6 70 85.7 51.0 3.26 98.4 70 
14 0.450 86.4 61.7 1.30 98.9 76 90.5 48.9 4.47 98.6 76 
15 0.550 84.1 38.3 4.55 98.0 42 89.6 29.2 11.04 98.3 44 
16 0.592 78.0 53.6 0.62 97.5 57 71.1 62.2 3.71 96.0 55 
17 0.463 42.6 73.3 0.84 87.4 72 43.4 73.4 1.25 84.9 71 
18 0.500 81.0 45.0 4.39 97.0 51 86.3 41.5 8.55 98.0 51 
19 0.450 76.8 55.5 2.80 96.4 48 80.1 50.9 6.44 97.1 49 
20 0.400 79.2 52.1 4.73 97.7 57 76.9 53.6 5.36 96.6 55 
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Although differences between the measured results of the 
two algorithms are small, one trend is consistent: the per-
centage of contour points exceeding 250% of the prescrip-
tion dose is smaller in every case for plans obtained from the 
branch-and-bound algorithm than for plans obtained via the 5 
genetic algorithm. This suggests that the former approach 
may provide better control on irradiation to external healthy 
tissue. 
To visualize one instance of this, FIGS. la and ln 
illustrate the isodose curves for Patient 8 for the branch- 10 
and-bound and genetic methods. In each frame of FIGS. la 
and ln, the prostate contour is denoted by the dotted line, 
and the isodose curves for four distinct dose levels (0.5, 1.0, 
1.5, and 2.0 times the prescription dose) are shown as solid 
lines. The character "S" is used to denote the position of a 15 
seed. FIGS. la-ln show the isodose curves associated with 
the plan obtained via the branch-and-bound algorithm, and 
FIGS. lh-ln show the curves associated with the plan 
obtained via the genetic algorithm. Patient 8 provides an 
illustration of a trade-off that occurred in several cases: the 20 
percentage of contour points receiving 100% of the pre-
scription dose is lower for the plan obtained from the 
branch-and-bound algorithm than for the plan obtained from 
the genetic algorithm (80% versus 93%), while the percent-
age of points receiving less than 115% of the prescription 25 
dose is higher for the plan obtained via the branch-and-
bound algorithm (55% versus 38%). Again, this suggests 
that the branch-and-bound approach may provide better 
control on irradiation to healthy tissue. In both cases, the 
prescription isodose curves conform quite well to the pros- 30 
tate contours in slices 1-5 and less well in slices 6 and 7. 
However, careful inspection reveals that the prescription 
isodose curves in FIGS. la-lg conform slightly better than 
those in FIGS. lh-ln. In addition, the areas enclosed by the 
50% isodose curves are consistently smaller in FIGS. la-lg. 35 
FIGS. 2a-2d provide a graphical view of some of the data 
displayed in Table 3, plus data from a third approach-
branch-and-bound applied to (MIP Bl). The fact that case 17 
was difficult for all approaches stands out. Barring this one 
exception, FIG. 2d shows that all methods provided 40 
adequate coverage to the prostate-as measured by the 
percentage of uniformity points achieving at least 100% of 
the prescription dose (PrDose). It is also apparent from FIG. 
2d that (MIP A3 GA) (the genetic algorithm applied to (MIP 
A3)) yields a consistently higher percentage of contour 45 
points with dose value exceeding 250% of the prescription 
dose than either of the other two methods. In contrast, from 
FIG. 2c, the percentage of contour points achieving a dose 
level less than 115% of the prescription dose was generally 
smallest for plans associated with (MIP Bl BB) (the branch- 50 
and-bound algorithm applied to (MIP Bl)). These last two 
observations suggest that, among the three approaches, the 
gradient of the isodose contours associated with dose levels 
less than the prescription dose is generally steepest for (MIP 
Al BB). 55 
The mixed integer programming framework provides a 
very versatile environment for modeling brachytherapy 
treatment planning. The results of the numerical experi-
ments presented herein show that this modeling paradigm 
coupled with appropriate optimization algorithms produce 60 
high-quality treatment plans in a fraction of the time (5-15 
minutes) required by a human planner using traditional 
manual approaches (upwards of 4 hours). Although the 
results disclosed herein were not directly compared to those 
produced via manual approaches, based on the judgment of 65 
an experienced urologist and radiation oncologist, the com-
puterized methods herein yield plans which use fewer seeds, 
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provide better dose homogeneity within the target volume 
and lower irradiation to nearby external healthy tissue than 
plans obtained via manual methods. 
Intensity-Modulated Conformal Treatment Planning Using 
Biological Imaging 
Permanent implantation of radioactive seeds is becoming 
an increasingly popular treatment modality for early-stage 
prostate carcinoma. Typically, 60-150 radioactive seeds 
(125I or 103Pd) are permanently implanted within the prostate 
in a specified geometric pattern to deliver a minimum 
peripheral dose of approximately 120--144 Gy. Transrectal 
ultrasound imaging (TRUS) can now be used to guide seed 
placement within the prostate, and real-time treatment plan-
ning algorithms are beginning to be used to determine the 
"ideal" seed placement within the prostate. True optimiza-
tion of dose distributions, however, is still not possible 
because of uncertainties in tumor position within the pros-
tate. This uncertainty forces the radiation oncologist to 
deliver maximum dose to the entire gland which in turn 
results (usually) in higher than optimum dose to the urethra. 
Unlike external-beam therapy, moderate (grade 2) urethral 
complications (e.g., urinary frequency and urgency neces-
sitating medications for symptomatic relief) remain the 
single most important limitation in prostate implants, as it is 
often physically impossible to reduce the radiation dose to 
the urethra without compromising the dose distribution to 
the prostate. These side effects, while not severe, can have 
a significant impact on the patients' overall quality of life. 
While urinary side effects may be inevitable for patients 
treated with prostatic implantation, it is plausible that with 
improved optimization techniques and intra-operative cor-
rection protocols to further enhance needle distribution and 
seed placement, these side effects will be reduced without 
compromising local control. 
Current implantation techniques do not incorporate some 
biological factors in the planning process. A recently devel-
oped rectal magnetic resonance (MR) coil now permits 
functional imaging of the prostate via MR spectroscopy 
(MRS). Localized MRS spectra can map citrate and choline 
concentrations within the prostate. In the peripheral zone the 
relative levels of these two compounds identify regions of 
prostate carcinoma with actively proliferating tumor cells. 
Currently, MRS images have spatial resolution of 6 mm, and 
this permits locating tumors to specific sites of the prostate. 
This information can be incorporated into real-time treat-
ment planning calculations wherein radioactive seeds can 
preferentially be placed in regions of the prostate identified 
as tumor, without (needlessly) increasing dose to the urethra. 
In this example we describe a treatment planning system 
used at our institution for implementing prostate implants 
using biological imaging. In designing this system several 
issues were considered: 
a) The feasibility of designing a computerized planning 
system capable of generating treatment plans with 
localized escalated dose (hot spots) in identifiable 
tumor regions while maintaining a minimal urethral 
dose, 
b) The registration of MRS information to ultrasound 
images, and 
c) The biological significance of dose escalation: given 
that the dose inside the prostate is already larger than 
the prescription (peripheral) dose, does selectively 
increasing the dose in some volumes result in enhanced 
local control. 
We illustrate the MRS-guided dose-escalation approach 
with an actual patient case, and compare-using a model of 
tumor control probability (TCP)-plans designed with or 
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without the benefit of the MRS data. The MRS-guided 
approach is one example of intensity-modulated conformal 
treatment. 
Example Intensity-Modulated Conformal Treatment 
1H magnetic resonance spectroscopic imaging (MRSI) 5 
can provide a window on the metabolism in the prostate. The 
major metabolites observed in an in vivo proton NMR 
spectrum from the normal prostate peripheral zone are 
choline-containing compounds (3.21 ppm), creatine (3.02 
ppm) and citrate (a doublet of doublets at 2.5-2.8 ppm). The 10 
choline (Cho) peak is comprised mainly of choline, phos-
phocholine and glycerophosphocholine. These compounds 
are constituents of membrane synthesis and degradation 
pathways and have been shown to be elevated in many 
malignancies. The creatine (Cr) peak is comprised of ere- 15 
atine and phosphocreatine. Citrate is synthesized, stored and 
secreted by glandular tissue in the prostate. 
In attempting to characterize prostate tissue by NMR 
spectroscopy, localization of spectra to small volumes 
within the prostate is essentially due to spatial variations in 20 
metabolite levels within the normal zonal anatomy as well as 
those that arise due to cancer. The group at the Magnetic 
Resonance Science Center at the University of California at 
San Francisco (UCSF) has developed techniques for acquir-
ing proton MRSI data from the prostate at high resolution 25 
(0.24 cm3 voxels, 6.2 mm in-plane resolution) with excellent 
suppression of water and lipids. 
In vivo NMR of the normal prostate has shown that the 
peripheral zone contains higher levels of citrate than the 
central gland. In prostate cancer, choline-containing com- 30 
pounds have been shown to be elevated while citrate is 
reduced in agreement with previous extract studies. The 
ratio of [ Cho+Cr ]/Cit was found to differentiate cancer from 
healthy peripheral zone tissue in all cases using a value of 
0.86 (three standard deviations above the mean normal 35 
peripheral zone ratio) as the demarcation line. Using this 
criterion, recent retrospective studies have shown excellent 
agreement between 1H MRSI and step-section histopathol-
ogy in localizing cancer to a sextant of the prostate. 
Data were acquired as follows: Using a General Electric 40 
Signa 1.5 Tesla MR Scanner. Radiofrequency (RF) excita-
tion was achieved by using the whole body birdcage reso-
nator and the NMR signal was received using a 4 element 
phased array antenna (G.E. Medical Systems, Milwaukee, 
Wis.) combined with an expandable MRinnervu endorectal 45 
probe (Medrad Inc., Pittsburgh, Pa.) for high sensitivity. The 
endorectal probe is comprised of a single loop surface coil 
mounted inside an inflatable casing. The probe is lubricated 
with K-Y jelly and inserted by a staff radiologist into the 
rectum of the patient where it is inflated with 100 cc of air 50 
to ensure proper operation of the antenna as well as good 
positioning adjacent to the prostate. 
Following positioning of the endorectal probe, sagittal 
Tl-weighted scout images were acquired, followed by 
Tl-weighted axial images (field of view (FOY) 14 cm, 5 mm 55 
slice thickness, 1 mm gap), T2-weighted axial images (FOY 
14 cm, slice thickness 3 mm, gap 0), and T2-weighted 
coronal images over the prostate (FOY 17 cm, slice thick-
ness 3 mm, gap 0). The pulse sequence program utilized for 
the spectroscopic acquisition utilizes the PRESS double spin 60 
echo technique to excite a rectangular volume containing the 
prostate. Prior to spectroscopic imaging, the water signal 
from the PRESS-excited volume is shimmed automatically 
with manual adjustment if necessary. Mapping of metabo-
lites over a 50-cm field of view (FOY) is performed using 65 
chemical shift imaging (CSI) to encode (6.25)3 mm3 voxels. 
Suppression of water and lipid is performed using the 
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BASING technique. The spectroscopic acquisition requires 
17 minutes, whereas the full examination requires approxi-
mately one hour. 
Following acquisition, images and spectral data were 
transferred to a Sun Ultrasparc Workstation (Sun 
Microsystems, Mountain View, Calif.) for processing. Pro-
cessing of the spectral data includes 2 Hz Lorentzian 
apodization in the time domain followed by 4-dimensional 
Fourier transform and automated frequency, phase and base-
line correction of each voxel using a combination of soft-
ware routines. Data are zero-filled in the superior-inferior (z) 
dimension resulting in effective resolution of 3.1 mm. Peak 
areas of Cho, Cr and Cit are calculated by numerical 
integration over the spectral ranges corresponding to each 
metabolite. Peak areas and ratios of [Cho+Cr]/Cit are cal-
culated and may be displayed as part of the spectral grid. 
Data are displayed overlaid on the corresponding 
T2-weighted images. 
In an example of a MRSI data set acquired at this 
institution, the subject was previously untreated with a 
Gleason grade of 7 and a PSA level of 8 ng/ml. On the 
T2-weighted image, periprostatic lipids are bright, with 
normal central gland appearing hypointense to healthy 
peripheral zone. The peripheral zone in this image shows a 
darker region in the central, posterior aspect, which would 
be considered suspicious for cancer. Spectra were classified 
as "healthy" peripheral zone (H) if [Cho+Cr]/Cit<0.76, 
"suspicious for cancer" (SC) if 0.76<[Cho+Cr]/Cit~0.86 or 
"very suspicious for cancer" (VC) if [Cho+Cr]/Cit>0.86. 
Spectra with poor metabolite signal-to-noise ratio or con-
tamination by lipid were classified as non-diagnostic (ND). 
Voxels in the central gland were not assessed. Asterisks are 
used to indicate voxels comprised of mixed peripheral zone 
and central gland. From left to right in the lowest row of 
voxels, the spectra show a transition from healthy peripheral 
zone to suspicious.for cancer. The fifth voxel from the left in 
this row is labeled healthy strictly using the UCSF criteria; 
[Cho+Cr]/Cit was 0.7. Several peripheral zone voxels were 
considered nondiagnostic based on the low signal-to-noise 
ratio. 
Registration of the MRS Information to Ultrasound Images 
The MR images used for spectral analysis of the prostate 
are obtained with a rectal probe that is inflated to a total 
volume of about 100 cc. Under these conditions the prostate 
gland is pushed in the anterior direction against the pubic 
bone and thus assumes a slightly flattened shape. Since the 
implant procedure, and accompanying treatment planning, 
are based on the intraoperative ultrasound study where the 
prostate is uncompressed, it is important to devise a proce-
dure for mapping points of interest from the MRS to the 
ultrasound (US) images. 
Changes in the shape of the prostate volume during MR 
spectroscopy are indicated by two MR studies of the same 
patient-{)ne with a body coil and the other with the rectal 
probe. We find that within a good approximation the total 
volume of the prostate remains constant. To map prostate 
voxels between the MR and US volumes we have assumed 
that points within the gland maintain the same relative 
position with respect to the axial contours of the prostate, 
and have no displacement in the superior-inferior direction. 
Thus, relative to the central axis of the gland (AB or A'B') 
the coordinates of point E in the US image corresponding to 
point E' in the MR volume are obtained using the following 
proportions: 
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A'C' AC C'E' CE 
Ji = A' C' = AB Ji = C' D' = CD 
(6) 
22 
images) have escalated lower bound and no upper bound; 
while the urethra has an upper bound and a lower bound 
which the clinicians consider necessary to eradicate micro-
scopic traces of tumor cells. 
5 
The (approximate) validity of this scheme has been con- We illustrate the MR-guided dose escalation approach via 
the automated planning system on an actual patient case. 
The prescription dose was 144 Gy using 125I seeds and the 
volume of the prostate was 38.1 cm3 . For the volume of the 
tumor region we have used three different values: 1.36, 2.35 
firmed with an MR study of a patient who had previous seed 
implantation. It was thus possible to identify the same seeds 
in images of the normal-shaped and MR-deformed prostate 
and verify directly the applicability of the expression, Eq ( 6) 
above. We find that the ratios in Eq (6) agree within 7% (3 
mm out of a 4-cm gland) which appears acceptable consid-
ering uncertainties in tumor detection (the MRS voxel size 
is 6x6x3 mm3 ), prostate contours, seed placement and also 
seed migration post-implantation. 
Optimization Planning System 
The optimization module used in our treatment planning 
system uses the integer programming technique. Linear 
programming (LP) has been highly successful as a tool for 
external beam radiation treatment planning. It has only 
recently been explored as a viable tool for determining 
optimal seed placement in brachytherapy. The LP models 
that we have developed for treatment planning in prostate 
brachytherapy involve both discrete (0/1) and continuous 
variables. In general, such mixed-integer linear programs 
(MIPs) are more difficult to solve than their continuous 
counterparts. Although optimization software capable of 
solving general MIPs exists on the market, the biggest 
successes in solving real MIP instances have come from 
solvers tailored to the specific structure of the problem at 
hand. 
Data for a patient include discretized representations of 
slices of the tumor site and neighboring healthy organs, and 
pre-specified target bounds for the dose. A grid of potential 
seed positions and exposure rate constants for the radioac-
tive sources are also recorded during the actual implant 
procedure. Values of Lp within the target are varied accord-
ing to the tumor cell density as determined from MRS. 
One possible approach is to identify a maximum feasible 
subsystem. This is the essence of our first model (MIP A). 
10 and 3.71 cm3 in order to verify (see next section) the 
sensitivity of the plan to this parameter. In each case the 
tumor was centered at the MRS-positive voxels. Bounds of 
100% to 120% were imposed on the urethra. Bounds of 
100% to 150% were placed on the uniformity points, and 
15 lower bound of 105% and no upper bound was placed on the 
tumor region. In two slices corresponding to the tumor 
location relative to the position of the urethra; the tumor 
volume is 1.36 cm2 . We clearly observe dose escalation 
around the tumor region in slice 1. In slice 2, where the 
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tumor spot is in the vicinity of the urethra, the dose received 
by the urethra is kept within the strict pre-set levels and 
reasonable escalation is observed in the tumor area. Dose-
volume histograms for the plans described above are shown 
in FIGS. SA, SB, SC, SD, SE and SF. The three curves in 
each graph correspond to: a) pockets of tumor identified via 
25 MRS, b) the rest of the prostate, and c) "healthy" tissue; this 
denotes tissue immediately outside the prostate as defined by 
the intersection of the prostate volume with a rectangular 
box that contains the prostate. For each tumor volume, the 
two sets of DVH curves represent, respectively, plans with 
30 or without dose escalation in the tumor pockets. Also 
indicated in the figures (vertical line) is the prescription 
dose. Notice that in both plans the curves for the normal 
tissue remain the same. For the escalated plan the dose in the 
remaining prostate is slightly lower; however in the pockets 
35 with tumor cells the dose is significantly larger than in the 
plan without dose escalation. A biological interpretation of 
these results is given below. 
By introducing additional 0/1 variables to capture whether a 40 
constraint is satisfied or not, one can directly maximize the 
number of points satisfying the specified bounds. Clinically, 
this corresponds to maximizing the tumor volume satisfying 
the respective bounds. In practice, achieving the target 
bounds for certain points may be more critical than achiev- 45 
ing the target bounds for certain other points. In this case, 
one maximizes a weighted sum, ~p(apvp+~pwp), where the 
more critical points receive a relatively larger weight. 
Table 4 shows the minimum and maximum dose in the 
urethra for plans calculated for the three tumor volumes 
considered above. Table 5 indicates, for each plan, the 
percentage of urethra volume in two dose ranges. 
TABLE 4 
Minimum and maximum doses in urethra (Gy); prescription dose: 144 Gy 
Standard plan MRS-guided plan 
Tumor (Plan A) (Plan B) 
In another embodiment (MIPB) continuous variables are 
used to capture the deviations of the dose level at a given 
point from its target bounds and minimize a weighted sum 
of the deviations, such that: 
n n 
~ D(llP-X1llJx1 +yp <: Lp ~ D(llP-X1llJx1 -Zp:;; Up, 
(7) 
j=l j=l 
where YP and Zp are non-negative, continuous variable. 
In this model the values UP are obtained, as an example, 
from normal-tissue complication probability (NTCP) distri-
butions. The objective for this model takes the form: mini-
mize ~p(apyp+~pzp), where ap and ~P are non-negative 
weights selected according to the relative importance of 
satisfying the associated bounds. 
We note that the dose upper and lower bounds in con-
straints Eq(3) can be strategically set, using the experience 














Minimum Maximum Minimum 
dose dose dose 
146.0 172.7 144.3 
146.0 172.7 144.3 
146.0 172.7 143.3 
TABLE 5 
Dose-volume distributions for urethra 
(percentage of volume in each dose interval) 
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The Potential Biological Significance of MRS-Guided 
Treatment Planning 
A typical tumor comprises a heterogeneous collection of 
cells of different radiosensitivity and/or cell proliferation 
kinetics. Nonetheless, it is generally understood that cells 5 
that are radioresistant and/or rapidly proliferating will con-
trol almost entirely its response to radiation treatment. In this 
sense, the tumor parameters used below are meant to rep-
resent this particular group. To the extent that MRS can be 
taken as a fingerprint for faster-proliferating tumor cells, 10 
recognizing regions with larger density of such cell popu-
lations could be consequential in terms of tumor local 
control. To examine this point, we compare below-using a 
series of hypothetical tumor parameters-the TCP for two 
optimized plans (same patient) designed to incorporate (plan 
B) or omit (plan A) the MRS information. Specifically, we 15 
are interested in: a) the maximal TCP gain obtainable by 
incorporating MRS information in treatment planning, and 
b) the largest fractional tumor volume for which MRS-
guided planning remains useful (clearly, if tumor cells are 
uniformly spread throughout most of the prostate volume the 20 
gain would be insignificant). 
For a tumor containing initially (before treatment, at time 




TCP(t) = 1 - ----------
! + bS(t)elh-dit (' dit' 
Jo S(t' )elh-d)t' 
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cells. A justification of the numerical values selected for 
these parameters is now given. 
For a and ~we have used values determined from in vitro 
cell survival measurements; of the two lines of prostate 
tumor cells studied, one radiosensitive ( a=0.487 Gr1 , 
~=0.055 Gr~ and the other radioresistant (a=0.155 Gr1, 
~=0.052 Gr ) we have selected the latter one. A recent 
publication reports cell kinetic measurements for prostate 
cancer cells: for five different tumors the potential doubling 
time, T Pot' was found to vary between 16 and 61 days and 
we take here Tp
0
,=l6 d. The same report estimates the cell 
loss factor to cjl=0.75. For the sublethal damage repair 
constant we take t0 =1 h, in line with numerous experimental 
determinations of this quantity; the precise choice of this 
quantity is not critical because for these forms of treatment 
TCP is rather insensitive to changes in t0 . 
The determination of the number of clonogenic cells in a 
tumor remains a matter of controversy. Several methods 
have been suggested, for instance using the normalized dose 
gradient y, but generally the numbers thus obtained appear 
rather unrealistic. For prostate, the following formula for 
calculating the volume, V, of prostate cancer cells has been 
suggested: 




Here PSA is the amount of prostate specific antigen, PV is 
the prostate volume as determined, for instance, by tran-
Here S(t) is the survival probability at time t of tumor cells, 
and b and d are, respectively, the birth and death rates of 
these cells. Equivalently, b=0.693/Tp
0
, and d/b is the cell 
loss factor ( cjJ) of the tumor. In this expression t refers to any 
time during or after the treatment; typically, one would take 
for t the end of the treatment period or the expected 
remaining life span of the patient. In practice, for permanent 
implants t would be made sufficiently large to satisfactorily 
approximate TCP( oo ). 
30 srectal ultrasound, and PSAL is the PSA leak into the serum 
(ng/ml) per unit volume (cm3 ) of cancer cells. The denomi-
nator in Eq(ll) represents cancer-specific PSA, that is PSA 
corrected for the contribution of benign epithelial cells; 0.2 
is the estimated fraction of epithelial cells and 0.33 is their 
35 corresponding PSAL. A paper reports PSAL values as a 
function of Gleason score, G. We have fitted these values to 
the following empirical equation: 
An actual calculation of TCP requires an explicit expres- 40 
sion for S(t). For simplicity and convenience we shall use 
the linear-quadratic expression: 
(9) 
PSALng cm3/m/=42.3exp(-0.749G) (12) 
With this, the number of cancer cells is n=p V, where p is the 
volume density of cells in the prostate tumor; here we take 
p=l09 cells/cm3 . Using Eqs(ll, 12), the three tumor vol-
umes considered below (1.36, 2.35, 3.71 cc) can be taken to 
represent, for instance, a patient with G=5 and PSA=3.6, 4.6 
and 6.0 ng/ml, respectively. There are, of course, other 
where D is the total dose delivered up to time t, and thus 
a function of time. The function q(t) makes explicit the 
repair of sublethal damage. For a situation where the dose 
rate decreases exponentially: 
45 PSA-G combinations that lead to the same values of V. 
q(t) = (10) 50 
-------- e-(A+µ)t + µ 2(At)2 [ { 1 - e-211) 1 + e-211 l 
(µtf(l _ ,'2/µ2)(1 _ e-lt)2 2At 2 
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y is the radioactive decay constant of the radioisotope (e.g. 
for 125I it is 1.152 10-2 d-1) and µ=1/t0 , where t0 is the 
average time for the sublethal damage repair, typically of the 
order of one hour. Taking the product of TCP values for 
groups of cells exposed to the same dose accounts for dose 
inhomogeneity in the tumor. 60 
The six parameters needed in this calculation are: a, ~, t0 , 
T Po,( =0.693/b ), cp( =d/b) and n. Other than n, it is of course 
quite unlikely that any particular tumor will contain cells 
that have unique values of these quantities. As already 
indicated, the numbers used hereinafter for evaluating the 65 
TCP should be taken to represent the response of the 
fast-proliferating and/or radioresistant segment of tumor 
In Table 6 we compare TCP for MRS-guided and standard 
plans. These results were obtained by assuming that: a) all 
radioresistant tumor cells are located in the MRS-positive 
volumes and b) other tumor cells do not affect significantly 
the TCP. Without assumption (b ), the numbers given in 
Table 6 are only upper limits of the actual TCP values. Thus, 
for this particular set of parameters and for this patient, Table 








Estimated TCP values 
(n = 1.36 109 cells. PV = 38.1 cm3) 
Standard plan MRS-guided plan 




Ratio of Plan B 




The MRS-guided treatment plan appears consistently (and 
significantly) superior to the standard plan. As anticipated, 
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as the tumor volume increases the difference between the 
two plans shrinks. 
TCP; for individual subgroups of cells, i, treated each at 
the same dose, D;, indicates that the final TCP 
26 
tigate the possibility of utilizing projected target volumes at 
later times to assist in the planning process. 
The effect of edema associated with prostate implants has 
been reported. In particular, Waterman et al. (Waterman F 
(which is equal to I) TCP;) 
5 M, Dicker AP. Effect of post-implant edema on the rectal 
dose in prostate brachyterapy, International Journal of 
Radiation Oncology and Biological Physics, 1999; 
45:571-576) described the duration and magnitude of edema 
via an analysis based on serial CT scans. If V0 denotes the 
10 prostate volume immediately after implantation, then the 
prostate volume at time t, V,, after implantation can be 
approximated by the formulation 
is essentially determined by contributions from the lowest 
dose bins. This makes makes the point that treatment-plan 
optimization must focus on increasing the lower dose thresh-
old in tumor-containing voxels rather than on the overall 
shape of the dose-volume distributions. It also emphasizes 
the need for accurate seed positioning in prostate implants. 15 
This treatment planning system for prostate implants 
makes use of biological imaging. In a typical implant the 
dose delivered to the gland is equal to or larger than the is 
prescription isodose, which is usually meant to cover the 
periphery of the prostate. The dose distribution inside the 20 
prostate is highly non-uniform. There is enough justification 
to intentionally place the (inevitable) hot spots of the plan in 
regions potentially known to contain pockets of radioresis-
tant tumor cells. Plans that have the same prostate coverage 
by the prescription isodose are not necessarily "the same". 25 
To the extent that MRS can detect fast-proliferating tumor 
cells, using "reasonable" radiobiological parameters and a 
TCP model, incorporating this information in the treatment 
planning process may lead to substantial improvements (e.g. 
45%) in local control. The magnitude of the TCP 30 
enhancement, and therefore the risks of ignoring the MR 
data, appear to be more substantial when the tumor is well 
localized. The disclosed optimization algorithm is capable 
of escalating the dose in individual voxels without affecting 
the healthy tissue surrounding the prostate and the urethral 35 
dose. 
It is an advantage of MR-guided treatments to allow the 
possibility of dose de-escalation away from tumors, thus 
reducing toxicity in adjacent healthy tissues. 
Determining an Effective Planning Volume for Permanent 40 
Prostate Implants 
When planning a brachytherapy prostate implant, the 
planning target volume (PTV) for the prostate is typically 
based on a medical image taken during a simulation session 
several days prior to the implantation. Unfortunately, since 45 
the prostate at the time of implantation is often swollen (due 
to the insertion of needles) the pre-implant PTV may not 
provide an accurate representation of the prostate at implant 
time. Hence, a plan based on the pre-implant PTV, however 
well designed, may not provide the desired dosimetry for 50 
effectively treating the diseased prostate. 
As sophisticated computerized optimization algorithms 
become more integrated into treatment planning systems, 
the need to design plans days in advance of implantation will 
diminish, and planning will likely occur immediately prior 55 
to implantation. In particular, it is reasonable to design plans 
based on the swollen prostate. Nevertheless, by itself, the 
merging of the planning process with the implantation 
procedure may not provide improved dosimetry to the 
prostate. A plan based on the swollen prostate volume may 60 
conform well to the swollen prostate, but it may not provide 
good dosimetry over time as shrinkage occurs. 
Motivated by the fact that post-implant seed movement 
and prostate swelling and shrinkage inevitably occur, we 
investigate herein the problem of determining an "effective 65 
planning target volume" (EPTV) for permanent implants in 
prostate cancer treatment planning. In particular, we inves-
V,= V
0
[ 1 +LI. V( e-o.o93<)/T -1) ], (13) 
where li. V is the initial relative increase of the edema, and T 
is the half-life of edema decay. 
We propose and analyze single-period and multi-period 
time-dependent dosimetric treatment planning models span-
ning a period of thirty days. In particular, the target volume 
at day 0 (swollen prostate) and projected target volumes at 
days 6, 12, 18, 24 and 30 (based on Eq (12)) are used in 
formulating the models. Corresponding to each model, an 
optimal treatment plan is obtained via an automated plan-
ning system. The dosimetric coverage and conformity over 
a period of thirty days are then compared. Based on the 
comparison study, we gain insight into how one might arrive 
at an effective planning target volume-a volume upon 
which the initial planning configuration should be deter-
mined. 
Lett be the time from the initial implantation; and let P(t) 
denote the target prostate, D(t) the dose that remains to be 
absorbed, and S( t) the potential seed positions at time t. The 
initial values, P(O), D(O) and S(O), correspond, respectively, 
to the initial (swollen) prostate after insertion of needles, the 
prescription dose specified by the clinician, and the initial 
potential seed positions. To approximate the shrinkage of the 
edema and seed displacement, we assume for the purposes 
of this study that the edema volume at time 0 is 1.414 times 
the size of the "normal" volume of the prostate, and that 
shrinkage occurs uniformly towards a point source specified 
as the center of mass of the swollen prostate at time 0. Based 
on this assumption, each linear dimension at time 0 is scaled 
by the cubic root of this volume change (1.122), and the 
position of a point source at time t along a single dimension 
is approximated by the equation 
n 
TD(P) = ~ D(llP- X1ll)x1 
j=l 
(14) 
where x0 is the coordinate along the given dimension of the 
point source at time 0, xc is the associated coordinate for the 
center of mass at time 0, and T is the half-life of edema 
decay. (For this example, we assume the half-life of edema 
decay is 15 days.) Since the movement of implanted seeds 
are affected by the movement of cells and tissues inside the 
prostate, it is reasonable to assume that seed movement also 
approximately follows the linear reduction given by equa-
tion (14). 
For both the single-period and multi-period treatment 
planning models, we focused on a 30 day time horizon, and 
considered six specific points in time: t=O, 6, 12, 18, 24, 30 
days. For the single-period model, for each of the specified 
times, a treatment plan was derived based on the projected 
volume and seed positions at that time. (The automated 
treatment planning system used to derive the treatment plans 
is described above) Once derived, the dosimetry associated 
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with a plan was measured at all of the six specified times 
(t=O, 6, 12, 18, 24, 30); at each time taking into account the 
projected shrinkage of the prostate and shifting of seeds. 
28 
over a period of 30 days. We notice that the initial prostate 
volume after needle insertion induces the highest normal 
tissue irradiation over a period of 30 days. 
Tables 9 and 10 and FIG. 6B summarize the results for the The idea of a multi-period model is to consider more than 
a single time period when deriving a plan. For the study 
described herein, dosimetric constraints to assist in obtain-
ing conformal prescription isodose curves at mutliple time 
periods were imposed. A treatment plan was then designed 
(again using the system described above) to satisfy the 
maximum number of dosimetric constraints across the 
multi-period time horizon. Specifically, we considered five 
two-period models. For each model, dosimetric constraints 
based on time 0 and time t were imposed, where t=6, 12, 18, 
24, 30. As with the single-period models, dosimetry mea-
sures (coverage and conformity) resulting from each plan 
were analyzed over the thirty day horizon. 
5 two-period model. Compared to FIG. 6A, the overall cov-
erage for the two-period plans over the 30 day horizon are 
uniformly better than those obtained from the single-period 
plans (comparing corresponding values for t1). For t1 =6 and 
t1 =12 the conformity results are only marginally different 
10 
than the corresponding single-period results. However, the 
results are more mixed for larger values of t1 . For instance, 
FIG. 6B illustrates that for t1 =30, the conformity index dips 
at t=30. This is, of course, due to the fact that the model for 
t1 =30 is emphasizing conformity on day 0 as well as day 30. 
15 
However, we also notice significant improvement in the 
coverage for this plan over the 30 day horizon. 
Dosage Variations with Time 
Two criteria were used to measure the quality of the 
resulting plans. Conformity at time tis computed as the ratio 
of the total volume enclosed by the isodose surface D(t) to 
20 
the target volume enclosed by this same surface. Coverage 
at time t is computed as the ratio of the target volume 
enclosed by D(t) to the total target volume. Hence, a 
conformity index is always greater than or equal to 1, and a 
coverage index is always less than or equal to 1. In either 
25 
case, an index value of 1 indicates perfect conformity/ 
coverage. 
Tables 7 and 8 summarize the results for the single-period 
model. Each column gives the mean, maximum and mini-
mum of the conformity (coverage) indices at times 0, 6, 12, 
30 
18, 24, 30 for the plan generated from the data specified by 
P(t1), D(t1 ) and S(t1). 
TABLE 7 
Conformity statistics for 30 day time horizon 35 
using single-period model plan based on P(t,). D(t,). S(t,). t, ~ 
statistic 
0 12 18 24 30 
40 
mean 1.2692 1.2223 1.1743 1.1538 1.1289 1.1193 
max 1.3649 1.3060 1.2505 1.2271 1.1928 1.1767 
min 1.141 1.1192 1.0876 1.0730 1.0579 1.0557 
45 
TABLE 8 
Coverage statistics for 30 day time horizon 
using single-period model plan based on P(t,), D(t,), S(t,), t,, 
statistic 50 
0 12 18 24 30 
mean 0.9963 0.9786 0.9769 0.9610 0.9583 0.9557 
max 0.9990 0.9962 0.9956 0.9828 0.9835 0.9813 
min 0.9890 0.9358 0.9317 0.9314 0.9310 0.9310 
55 
Note that in both tables a consistent trend is apparent: as 
t1 increases, both the conformity and coverage statistics 
decrease. In particular, the best coverage and the worst 
conformity is achieved when t1 =0; and conversely, the worst 60 
coverage and best conformity is achieved when t1 =30. Plans 
based on the initial data at t1 =0 provide over 99% coverage 
at all times, but have conformity indices reaching as high as 
1.36. Plans based on projected data at t1 =24 and t1 =30 yield 
over 93% coverage, while maintaining conformity indices 65 
less than 1.2 over the entire 30 day period. FIG. 6A shows 
a plot of coverage and conformity indices for the six plans 
TABLE 9 
Conformity statistics for 30 day time horizon using two-period model plan 
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The results reported here demonstrate that a planning 
method embodiments that takes into account prostate shrink-
age and seed displacement over time can be used to fine-tune 
the balance between coverage and conformity. In particular, 
if achieving good conformity is the higher priority it may be 
desirable to prepare a treatment plan embodiment based on 
the projected prostate volume at a later time. 
Conclusion 
While the invention has been described m detail in 
connection with the preferred embodiments known at the 
time, it should be readily understood that the invention is not 
limited to such disclosed embodiments. Rather, the inven-
tion can be modified to incorporate any number of 
variations, alterations, substitutions or equivalent arrange-
ments not heretofore described, but which are commensu-
rate with the spirit and scope of the invention. Accordingly, 
the invention is not to be seen as limited by the foregoing 
description, but is only limited by the scope of the appended 
claims. 
What is claimed is: 
1. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
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representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
30 
12. The method of claim 10, the method further compris-
ing determining the particular time associated with an effec-
tive planning target volume based on variations in a cover-
age ratio over time, the coverage ratio at a certain time associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid; 
5 determined by dividing a total target volume into a volume 
enclosed by an isodose surface at the certain time. 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
10 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 15 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
2. The method of claim 1, wherein each tissue point is 
associated with one tissue type of a plurality of tissue types. 20 
3. The method of claim 1, wherein 
a first tissue type of the plurality of tissue types is based 
on a first image formed by a first imaging device; and 
a second tissue type of the plurality of tissue types is 
based on a second image formed by a second imaging 25 
device. 
4. The method of claim 3, the step of representing a tumor 
and surrounding tissue further comprising the step of map-
ping a point in the second image to a corresponding point in 
the tissue grid. 
5. The method of claim 4, the step of mapping further 
comprising 
30 
determining a common tissue type apparent in images 
from the first imaging device and the second imaging 
device; 35 
measuring a scaling distance along an axis from a center 
of the common tissue type to an edge of the common 
tissue type; and 
computing a corresponding coordinate in the tissue grid 
based on a ratio obtained by dividing the scaling 
distance into a distance from the center to a coordinate 
of the point on the axis. 
6. The method of claim 3, wherein 
40 
the first imaging device is an ultrasound imaging device; 45 
and 
the second imaging device is a magnetic resonance spec-
troscopic imaging device. 
7. The method of claim 3, wherein 
the first tissue type is associated with undifferentiated 50 
normal tissue and cancerous tissue; and 
the second tissue type is associated with cancerous tissue. 
8. The method of claim 1, the step of representing a tumor 
and surrounding tissue based on biological imaging. 
9. The method of claim 1, wherein the tissue grid repre- 55 
sents the tumor and surrounding tissue at a particular time. 
10. The method of claim 9, further comprising mapping 
the three dimensional grid of potential seed locations at a 
time of seed insertion to a new grid of potential seed 
locations at the particular time. 60 
11. The method of claim 10, the method further compris-
ing determining the particular time associated with an effec-
tive planning target volume based on variations in a con-
formity ratio over time, the conformity ratio at a certain time 
determined by dividing a target volume to be enclosed by an 65 
isodose surface into a volume enclosed by that surface at the 
certain time. 
13. The method of claim 9, wherein the particular time is 
an imaging time when an imaging device is used to form an 
image of the tumor and surrounding tissue. 
14. The method of claim 9, wherein: 
the method further comprises 
mapping the tissue grid to a second tissue grid at a 
second time, and 
mapping the three dimensional grid of potential seed 
locations at a time of seed insertion to a second grid 
of potential seed locations at the second time, 
calculating a second objective value based on a second 
difference at each point of the second tissue grid at 
the second time, and 
varying the trial placement to obtain a second optimal 
value at the second time; and 
in step of setting the planned placement of seeds is 
further based on the trial placement that obtains the 
second optimal value. 
15. The method of claim 9, wherein: 
the method further comprises 
mapping the tissue grid to a second tissue grid at a 
second time, and 
mapping the three dimensional grid of potential seed 
locations at a time of seed insertion to a second grid 
of potential seed locations at the second time; and 
the step of calculating the objective value is further 
based on second differences at each point of the 
second tissue grid between a second amount of 
radiation based on the trial placement of seeds 
mapped to the second grid at the second time. 
16. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
wherein each tissue point is associated with one tissue 
type of a plurality of tissue types; 
wherein a first tissue type of the plurality of tissue types 
is associated with slowly proliferating tumor cells; 
wherein a second tissue type of the plurality of tissue 
types is associated with rapidly proliferating tumor 
cells; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each tissue 
point in the tissue grid; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 
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setting a planned placement of seeds based on the trial 
placement of seed that obtains the optimal objective 
value. 
17. The method of claim 16, the step of associating at least 
one of the upper bound and the lower bound further com- 5 
prising: 
determining whether the second tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the second tissue type is associate 
with the particular point, then associating no upper 10 
bound with the particular point. 
18. The method of claim 16, the step of associating at least 
one of the upper bound and the lower bound further com-
prising: 
15 
determining whether the second tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the second tissue type is associate 
with the particular point, then associating a particular 
lower bound with the particular point, the particular 
20 
lower bound greater than a prescription dose allowed 
for healthy tissue. 
19. The method of claim 16, the step of associating at least 
one of the upper bound and the lower bound further com-
prising: 
determining whether the first tissue type is associated with 
a particular point in the tissue grid; and 
25 
if it is determined that the first tissue type is associated 
with the particular point, then associating a particular 
lower bound with the particular point, the particular 30 
lower bound substantially equal to a prescription dose 
allowed for healthy tissue, and 
32 
determining whether the third tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the third tissue type is associate 
with the particular point, then associating no lower 
bound with the particular point. 
23. The method of claim 16, wherein: 
a third tissue type of the plurality of tissue types is 
associated with slowly proliferating tumor cells of a 
different gland; and 
the step of associating at least one of the upper bound and 
the lower bound further comprises: 
determining whether the third tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the third tissue type is associated 
with the particular point, then associating a particular 
upper bound with the particular point, the particular 
upper bound substantially greater than a prescription 
dose allowed for healthy tissue. 
24. The method of claim 16, wherein: 
a third tissue type of the plurality of tissue types is 
associated with slowly proliferating tumor cells of a 
different gland; and 
the step of associating at least one of the upper bound and 
the lower bound further comprises: 
determining whether the third tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the third tissue type is associated 
with the particular point, then associating a particular 
lower bound with the particular point, the particular 
lower bound substantially equal to a prescription 
dose allowed for healthy tissue. 
associating a particular upper bound with the particular 
point, the particular upper bound substantially greater 
than the prescription dose. 
25. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
35 comprising the steps of: 
20. The method of claim 19, wherein: 
a third tissue type of the plurality of tissue types is 
associated with slowly-proliferating cells of a different 
gland; and 
the step of associating at least one of the upper bound and 40 
the lower bound further comprises 
determining whether the third tissue type is associated 
with a particular point in the tissue grid; and 
if it is determined that the third tissue type is associated 
with the particular point, then associating a different 45 
upper bound with the particular point, the different 
upper bound substantially greater than the prescrip-
tion dose but substantially less than the particular 
upper bound associated with the first tissue type. 
50 21. The method of claim 16, wherein: 
a third tissue type of the plurality of tissue types is 
associated with non-tumor cells; and 
the step of associating at least one of the upper bound and 
the lower bound further comprises 
determining whether the third tissue type is associated 
with a particular point in the tissue grid; and 
55 
if it is determined that the third tissue type is associate 
with the particular point, then associating a particular 
upper bound with the particular point, the particular 60 
upper bound substantially equal to a prescription 
dose allowed for healthy tissue. 
22. The method of claim 16, wherein: 
a third tissue type of the plurality of tissue types is 
associated with non-tumor cells; and 65 
the step of associating at least one of the upper bound and 
the lower bound further comprises 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid, wherein a larger upper bound is 
associated for fast-proliferating tumor cells than for 
slowly-proliferating tumor cells; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
26. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
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representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points, wherein the tissue grid represents 
the tumor and surrounding tissue at a particular time, 
the particular time being an insertion time when the 5 
seeds are inserted with needles that cause swelling of 
the tumor and surrounding tissue; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
10 
varying the trial placement of seeds and repeating the step 15 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 
setting a planned placement of seeds based on the trial 20 
placement of seeds that obtains the optimal objective 
value. 
27. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
25 
representing a tumor and surrounding tissue as a prede- 30 
termined three dimensional tissue grid having a plural-
ity of tissue points, wherein the tissue grid represents 
the tumor and surrounding tissue at a particular time, 
the particular time being a post insertion time after the 
seeds are inserted with needles that cause swelling of 35 
the tumor and surrounding tissue, when the swelling 
has decreased; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid; 40 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
45 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 
50 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
28. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 55 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points, wherein the tissue grid represents 
the tumor and surrounding tissue at a particular time; 
60 
associating at least one of an upper bound and a lower 65 
bound for a dose of radiation received with each point 
in the tissue grid; 
34 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value; and 
determining shrinkage of the tumor and surrounding 
tissue with time based on a half-life decay of an initial 
increase in volume associated with insertion of needles 
into the tissue. 
29. The method of claim 28, the step of determining the 
shrinkage further comprising decreasing each linear dimen-
sion based on the cube root of the half life decay. 
30. A method for planning the placement of seeds for a 
brachytherapy treatment of diseased tissue, the method 
comprising the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid, the associating step further compris-
ing the step of estimating the reduction in tumor 
parameters corresponding to associating a different 
upper bound for fast-proliferating tumor cells than for 
slowly-proliferating tumor cells; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds and the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the step 
of calculating the objective value, resulting in addi-
tional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; and 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
31. A computer system for planning the placement of 
seeds for a brachytherapy treatment of diseased tissue, the 
computer system comprising: 
a computer readable medium; and 
one or more processors connected to the computer read-
able medium, the one or more processors configured to 
perform the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid 
of potential seed locations with a binary indicator 
variable; 
representing a tumor and surrounding tissue as a pre-
determined three dimensional tissue grid having a 
plurality of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each 
point in the tissue grid; 
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calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds an the 
at least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the 5 
step of calculating an objective value resulting in 
additional objective values; 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; 
and 
10 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
32. The computer system of claim 31, the step of repre-
senting a tumor and surrounding tissue based on biological 
imaging. 
33. The computer system of claim 31, wherein the tissue 
grid represents the tumor and surrounding tissue at a par-
ticular time. 
15 
34. The computer system of claim 33, further comprising 
mapping the three dimensional grid of potential seed loca- 20 
tions at a time of seed insertion to a new grid of potential 
seed locations at the particular time. 
36 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds an the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds to obtain an optimal 
value and repeating the step of calculating an objective 
value resulting in additional objective values; and 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
37. The computer readable medium of claim 36, the step 
of representing a tumor and surrounding tissue based on 
biological imaging. 
38. The computer readable medium of claim 36, wherein 35. A computer system for planning the placement of 
seeds for a brachytherapy treatment of diseased tissue, the 
computer system comprising: 
the tissue grid represents the tumor and surrounding tissue at 
25 a particular time. 
a computer readable medium; and 
one or more processors connected to the computer read-
able medium, the one or more processors configured to 
perform the steps of: 
representing a placement or non-placement of a seed in 30 
each point of a predetermined three dimensional grid 
of potential seed locations with a binary indicator 
variable; 
39. The computer readable medium of claim 38, further 
causing the one or more processors to perform the step of 
mapping the three dimensional grid of potential seed loca-
tions at a time of seed insertion to a new grid of potential 
seed locations at the particular time. 
40. A computer readable medium having stored thereon 
sequences of instructions for planning the placement of 
seeds for a brachytherapy treatment of diseased tissue, the representing a tumor and surrounding tissue as a pre-
determined three dimensional tissue grid having a 
plurality of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each 
35 sequences of instructions causing one or more processors to 
perform the steps of: 
point in the tissue grid, wherein the step of associ-
ating at least one of the upper bound and the lower 
40 
bound further comprises associating a larger upper 
bound for fast-proliferating tumor cells than for 
slowly-proliferating tumor cells; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
45 
radiation based on a trial placement of seeds an the 
at least one of the upper bound and the lower bound; 
varying the trial placement of seeds and repeating the 
step of calculating an objective value resulting in 
additional objective values; 
50 
selecting an optimal objective value from the calculated 
objective value and the additional objective values; 
and 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
w~. ~ 
36. A computer readable medium having stored thereon 
sequences of instructions for planning the placement of 
seeds for a brachytherapy treatment of diseased tissue, the 
sequences of instructions causing one or more processors to 
60 
perform the steps of: 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a placement or non-placement of a seed in 
each point of a predetermined three dimensional grid of 
potential seed locations with a binary indicator vari-
able; 
representing a tumor and surrounding tissue as a prede-
termined three dimensional tissue grid having a plural-
ity of tissue points; 
associating at least one of an upper bound and a lower 
bound for a dose of radiation received with each point 
in the tissue grid, wherein the step of associating at 
least one of the upper bound and the lower bound 
further comprising associating a larger upper bound for 
fast-proliferating tumor cells than for slowly-
proliferating tumor cells; 
calculating an objective value based on a difference at 
each point of the tissue grid between an amount of 
radiation based on a trial placement of seeds an the at 
least one of the upper bound and the lower bound; 
varying the trial placement of seeds to obtain an optimal 
value and repeating the step of calculating an objective 
value resulting in additional objective values; and 
setting a planned placement of seeds based on the trial 
placement of seeds that obtains the optimal objective 
value. 
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It is certified that error appears in the above-identified patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 3, 
Line 10, delete "la and ln" and replace with -- la - ln --. 
Column 17, 
Lines 9 and 11-12, delete "la and ln" and replace with -- la - ln --. 
Line 16, delete "la - ln" and replace with -- la - lg--. 
Column 35, 
Lines 5-7, delete "varying the trial placement of seeds and repeating the step of 
calculating an objective value resulting in additional objective values" and replace with 
-- varying the trial placement of seeds to obtain an optimal value for the objective 
value--. 
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Twelfth Day of August, 2003 
JAMES E. ROGAN 
Director of the United States Patent and Trademark Office 
